Obesity associated with longer survival for men with metastatic melanoma

(University of Texas M. D. Anderson Cancer Center) Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), investigators report in a study published in Lancet Oncology of 1,918 patients in six independent clinical cohorts.This effect, referred to as the 'Obesity Paradox,' principally manifested itself in men, said Jennifer McQuade, M.D., lead author and instructor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news